(C) | 1. |
¤¤¦~¨k©Ê¦]¬°¤UªÏ¤ô¸~¡A³J¥Õ§¿> 3.0 g/day¡A³Q¶EÂ_¬°µÇ¯f¯gÔ¸s(nephrotic syndrome)¡A·Ç³Æ±µ¨üµÇŦ¥ÍÀË(renal biopsy)¡C¯f¤HµL°ª¦åÀ£¡Bµ²¥Û©Î§¿¸ô·P¬V¯gª¬¡A¦ý¬O¨â¦¸§¿²GÀˬd³£¦³pyuria¡C³Ì¥i¯àªºµÇŦ¯f²z«¬ºA¬°:
|
A. | §½³¡µÇµ·²yµw¤Æ¯g[focal segmental glomerulosclerosis (FSGS)] |
B. | ·L¤p¯fÅܵǵ·²yµÇª¢(minimal change disease) |
C. | ½¤©Ê¼W¥Í©ÊµÇª¢[membranoproliferative glomerulonephritis (MPGN)] |
D. | ¿}§¿¯fµÇ¯fÅÜ(diabetic nephropathy) |
E. | ¦hÅnµÇ (polycystic kidney disease) |
|
(B) | 2. |
¤@¦ì38·³¤k©Ê¡A¹L¥h¨Å骬ªp¨}¦n¡Cªñ¨â¶g¨Ó¥X²{Ãþ¦ü·P«_¯gª¬¡B¹¼¤¤£®¶¡B¦åÀ£°¾°ª¡B¨¬³¡¤ô¸~¡B¤Î§¿¶q´î¤Ö¡C°µ§¿²GÀˬdµo²{: ¦å§¿¡B³J¥Õ§¿¡B©M¬õ¦å²y¶ê¬W¨I´í(RBC cast)¡C¦¹¯f¤HÀÀ±µ¨üµÇŦ¥ÍÀË(renal biopsy)¡A¥H¤UþºØ¯f²z«¬ºA³Ì¤£¥i¯à¥X²{:
|
A. | ·P¬V«áµÇª¢(postinfectious glomerulonephritis) |
B. | ¿}§¿¯fµÇ¯fÅÜ(diabetic nephropathy) |
C. | IgA nephritis
|
D. | À³¸ÓÃhºÃ¬O§_¦³¯T½H©ÊµÇª¢(lupus nephritis)ªº¥i¯à |
E. | «æ©Ê·s¤ë«¬µÇª¢(acute crescentic glomerulonephritis)
|
|
(A) | 3. |
ºC©ÊµÇŦ¯f(chronic kidney disease)»P§¿¬r(uremia)¯f¤H·|¦X¨Ö¦³¶t(Ca)-ÁC(P)²§±`»P°©¯fÅÜ¡C¨ä¥i¯àªº¯f¦]¦³: (1)°ª¦å¶t(hypercalcemia), (2)§C¦å¶t(hypocalcemia), (3)°ª¦åÁC(hyperphosphatemia), (4)§C¦åÁC(hypophosphatemia), (5)°Æ¥Òª¬¸¢¤®¶i(hyperparathyroidism), (6) ¯Ê¥F¬¡©Êºû¥L©RD, (7) £]2·L¤p²y³J¥Õ(£]2-microglobulin)°ï¿n ¡C¥H¤U¦óºØ²Õ¦X¾Ç²z¤W¤£¥¿½T¥BÁ{§É¤W³Ì¤Ö¥X²{ªº?
|
A. | 1 + 4 + 6 |
B. | 2 + 5 + 6 + 7 |
C. | 1 + 3 + 5 |
D. | 2 + 3 + 5 + 7 |
E. | 2 + 4 + 7 |
|
(B) | 4. |
¦³ÃöºC©ÊµÇŦ¯f(chronic kidney disease)»P°ª¦åÀ£ªº±Ôz¡A¦óªÌ¿ù»~?
|
A. | µÇŦ¯f(renal parenchymal disease)¬O³y¦¨Äòµo©Ê°ª¦åÀ£(secondary hypertension)³Ì±`¨£ªºì¦] |
B. | °ª¦åÀ£¤Þ°_ªºµÇŦ¦åºÞ¯fÅÜ¥HµÇµ·²y¤J²y¤p°Ê¯ß(preglomerular arteriole)¬°¥D¡A¦´Á¥Hfibrinoid necrosis©Îonion-skin lesion¬°¥D |
C. | µÇµ·²y¯fÅÜ(glomerular disease)¤@¯ë¨Ó»¡¤ñ°_µÇ¶¡½è¯e¯f(renal interstitial disease)§ó±`¦X¨Ö¥X²{°ª¦åÀ£ |
D. | ìµo©Ê°ª¦åÀ£¦bµÇŦ¥H¤Þ°_hyaline arteriolosclerosis»PµÇµ·²yµw¤Æ(nephrosclerosis)¬°¥D |
E. | ´c©Ê°ª¦åÀ£¥i¯à¤Þ°_¤ßŦ°IºÜ©M«æ©ÊµÇ°IºÜ |
|
(C) | 5. |
¦³Ãö¦ÛÅéÅã©Ê¦hÅnµÇ¯e¯f(autosomal dominant polycystitic kidney disease, ADPKD)ªº±Ôz¡A¦óªÌ¥¿½T?
|
A. | ±`¨Öµoªc§¿¹D·P¬V(urinary tract infection)¡A§Ü¥Í¯À¿ï¾Ü¥Hpenicillinµ¥¤ô·»©Ê§Ü¥Í¯À¹ïÅn¤º·P¬V(cystic infection)¬ï³z¤O¸û¦n |
B. | ±±¨î¦åÀ£¹ïADPKD¯fµ{¶i®i¦³§U¯q¡A¦bADPKD¤Þ°_¥½´ÁµÇŦ¯fªº¯f¤HÀ³ÄY®æ¶¼¹ºÞ²z±À¦æ§C³J¥Õ¶¼¹(low protein diet)¡A¯à©µ½wºtÅܦ¨§¿¬r¯g |
C. | ¥i¯à¦X¨Ö¯g¦³: ¨xÅn¸~(hepatic cyst), ¤ßŦ佤²§±`, Æ`¤º¦åºÞ½F, ¤j¸z¾Í«Ç(colonic diverticulae)µ¥ |
D. | ADPKD¦pªG¶i¦æ¦ÜµÇ°IºÜ¡A±µ¨ü¸¡½¤³zªR(peritoneal dialysis)ªº¦s¬¡²v·|¤ñ¦å²G³zªR(hemodialysis)©Î¤@¯ëµÇ°IºÜ¯f¤H®t |
E. | ADPKD¶i¦æ¦ÜµÇ°IºÜ¡A¤£©y±µ¨üµÇŦ²¾´Ó¡A¦]¬°¦s¬¡²v¤ñ¤@¯ë¤H®t |
|
(D) | 6. |
¦³¨Ç¨t²Î©Ê¯e¯f·|¼vÅTµÇŦ¦å¬y(renal vascular injury in systemic disease)¡A¦Ó¥X²{µÇŦ¯f¥ü¡C¦³ÃöªvÀøì«h¡A¤U¦C±Ôz¦óªÌ¥¿½T?
|
A. | Thrombotic thrombocytopenic purpura (TTP)Á{§Éªí²{¦³·»¦å©Ê³h¦å¡B¦å¤pªO¼Æ¥Ø°§C¡A©M¦å§¿¡CªvÀø¥H¿éª`¦å¤pªO(platelet)ÁB¥¿¾®¦å²§±`¬°¥D |
B. | Hemolytic uremic syndrome (HUS)¥i¥H¬O·P¬V©Îcyclosporin¤Þ°_¡A«æ©ÊÀøªkplasmapheresis¤ñplasma exchange®ÄªG¸û¦n |
C. | Scleroderma¯f¤H¦pªG¥X²{µÇŦ¦M¯g(renal crisis)¡A¦p´c©Ê°ª¦åÀ£¡BµÇ°IºÜ®É¡AÀ³Àu¥ý¿ï¥Îangiotensin receptor blocker (ARB)±±¨î¦åÀ£¡A¨ä¦¸¥i¦X¨Ö§Q§¿¾¯(diuretics)¡CACEI©ÎNSAID¥i¯à¥[«¦åºÞ¯fÅÜÀ³ÁקK¨Ï¥Î |
D. | µÇÀR¯ß®ê¶ë(renal vein thrombosis)ªºªvÀø¥Hanticoagulant¬°¥D¡A¦P®É¥i¹w¨¾ªÍ®ê¶ë(pulmonary embolization)ªº¦MÀI |
E. | Ãh¥¥¥Í²£¹Lµ{¤¤¦]¬°¥X¦å©Î¦åºÞ®ê¶ë¥X²{µL§¿(anuria)¡B«æ©ÊµÇ°IºÜ¡A¶EÂ_¬°¨â°¼µÇ¥Ö½èÃa¦º(bilateral renal cortical necrosis)¡C¹w«á³q±`80%¥i´_ì¡Aªø´ÁÅܦ¨§¿¬r¯g©Î³zªR¯f±w(dialysis-dependent)ªº¾÷·|«Ü§C |
|
(A) | 7. |
¤@¦ì¤¤¦~¨k©Ê¡A¹L¥h¯f¥v¨Ã¤£²M·¡¡A¥»¦¸¦]³J¥Õ§¿(proteinuria 3.1 g/day)±µ¨üµÇŦ¥ÍÀË(renal biopsy)¡CµÇŦ¯f²zµ²ªG¬°½¤©ÊµÇ¯fÅÜ(membranous nephropathy)¡A¤wª¾³o¬O¦¨¦~¤H³Ì±`¨£ªºµÇ¯fÅÜ(primary glomerulopathy)¤§¤@¡C¦pªG±ý¶i¤@¨B°l¬d¥i¯àì¦]»PªvÀø¡A¥H¤U±Ôz¦óªÌ¿ù»~?
|
A. | ¦p¸ß°Ý¯f¥v¡A¥i¯à»Pheroin/analgesics¨Ï¥Î¦³Ãö |
B. | Àˬd¦³µLÀù¯g¡A¦plung cancer, colon cancer¤§¥i¯à |
C. | ¬d¸ß¦ÛÅé§K¬Ì(autoimmune)¬ÛÃö¦]¤l¡A¦prheumatoid arthritisµ¥ |
D. | Àˬd¬O§_¦³ºC©Ê·P¬V¯g¡A¦p: hepatitis B, syphillisµ¥ |
E. | ¦]¬°³J¥Õ§¿¦h¡AÀ³¸Ó¨Ï¥Î§K¬Ì§í¨î¾¯(immunosuppressive agent)¡A¥i¥[¤W§Ü¾®¦å¾¯(anticoagulant)¹w¨¾®ê¶ë¯gµo¥Í |
|
(B) | 8. |
¦³ÃöÃĪ«µÇ¬r©Ê(nephrotoxin)ªºì¦]»PªvÀøì«h¡A¤U¦C±Ôz¦óªÌ¥¿½T?
|
A. | §Ü±Æ¥¸ÃĪ«cyclosporineªºµÇ¬r©Ê¬O¦]¬°³y¦¨¦åºÞ¦¬ÁY©ÒP¡A¥Dn³y¦¨µÇµ·²y²ÓM(renal mesangial cell)Ãa¦º(necrosis) |
B. | Contrast nephropathy»P¹L®ñ¤Æ²£ª«(reactive oxygen species)»PÅé²G¤£¨¬(volume depletion)¦³Ãö¡A¬G§Ü®ñ¤Æ¾¯(antioxidant)»P¾A·íÅé²G¸É¥R(hydration)¥i¾A·í°§Cµo¥Í |
C. | Aminoglycoside ©Îamphotericin-BªºµÇ¬r©Ê¬O¤@ºØallergic ¤ÏÀ³¡A³q±`¦b¨Ï¥Î24¤p®É´N¥iµo²{ |
D. | Rifampin»PNSAID (non-steroidal anti-inflammatory drug)«h¬O¯}ÃaµÇ¤pºÞ(renal tubule)²ÓM©Î°ô¶ë»·ºÝµÇ¤pºÞ©ÒP |
E. | ºë¯«¬ìÂå®v¨Ï¥Î¾YÆQ(lithium)¨ÓªvÀøbipolar disorder¡Aªø´Á¨Ï¥Î·|¤Þ°_¦h§¿¯g(polyuria)¡A¦pªG»¤µo¶¡½èµÇª¢(interstitial nephritis)«h«Ü¤Ö¶i¦æ¦ÜºC©ÊµÇ°IºÜ |
|
(D) | 9. |
¦³Ãö³zªRªvÀø³q¸ô(dialysis access)ªº³B¸mì«h¡A¤U¦C±Ôz¦óªÌ¿ù»~?
|
A. | ¦å²G³zªR¦åºÞ³q¸ô¦Ü¤Ö»Ý´£¨Ñ200-400 mL/minªº¬y³t¡A¤~°÷³zªR¤¤ª«½è¥æ´«¤§¥Î |
B. | ¦å²G³zªR¦åºÞ³q¸ô³Ì±`¨£¦³(a)¦ÛÅéúPºÞ(native arteriovenous fistula)¡B(b)¤H¤u¦åºÞ(arteriovenous graft), »P(c)¼È®É©ÊÀR¯ßÂùµÄ¾ÉºÞ(double-lumen catheter)¡C¿ï¾ÜªºÀu¥ý¶¶§Ç¬°(a)>(b)>(c) |
C. | ¸¡½¤³zªR¾ÉºÞ¦³¤@¬q¥Ö¤UÀG¹D(subcutaneous tunnel)¥i¥Î¨Ó©T©w¡B¹w¨¾²Óµßª½±µ¶i¤J¸¡½¤·P¬V |
D. | ¼È®É©ÊÀR¯ßÂùµÄ¾ÉºÞ(double-lumen catheter)¸m©ñ¦ì¸m¦Ò¶q¦åºÞ®ê¶ëªº¦MÀI¡G¥HÂê°©¤UÀR¯ß(subclavian vein)Àu¥ý¡A¨ä¦¸¬°¥~ÀVÀR¯ß(external jagular vein)¡B©ÎªÑÀR¯ß(femoral vein)¦ì¸m¡C |
E. | ®Ú¾Ú¬ã¨s: Dªº¤H(BMI>28.4) ¾A¦X±N¼È®É©ÊÀR¯ßÂùµÄ¾ÉºÞ(double-lumen catheter)¸m©ñ¦b¥~ÀVÀR¯ß(external jagular vein)¡A¦]¬°¬Û¸û©óªÑÀR¯ß(femoral vein)¦ì¸m¡A¤ñ¸û¤£·|¦³²Óµß´Fªø(conolization) |
|
(D) | 10. |
¤@¦ì46·³¤k©Ê¡A¤wª¾¦³ºC©ÊµÇŦ¯f(creatinine 5.2 mg/dL)¡A¨S¦³¿}§¿¯f©Î§K¬Ì²§±`¯f¥v¡A¤]¨S¦³Ãö¸`¯kµh¡BRaynaud's phenomenon¯gª¬¡C¥b¦~«e¦]¼Æ¦¸ªÍª¢¦í°|¡A´¿±µ¨ü¨â¦¸MRI»PÅã¼v¾¯(Gadolinium)ÀˬdªÍ³¡¯fªp¡C¯f¤H¥D¶D¥b¦~¨Ó¦³º¥¶i©Ê¥Ö½§Åܺò¡B¦â¯À¨I¾ý¡A±q¤â¸}©¹ÅX·F©µ¦ù¡A¦ý¬OÁy³¡µL²§ª¬¡AANAÀˬdµ²ªG§e³±©Ê¤ÏÀ³¡C¥H¤U¦óªÌ³Ì¥¿½T?
|
A. | ³o¬O§¿¬r¯gªº¨å«¬ªí²{ |
B. | »Ý¥[°µMRI(»ÝÅã¼v¾¯Gadolinium)Àˬd±Æ°££]2-microglobulin amyloidosisªº¥i¯à©Ê |
C. | ¦w±Æ°µ¥Ö½§¤Á¤ùÀˬd¬O§_¦³uremic neuropathy |
D. | ¥i¯à¬Onephrogenic systemic fibrosis |
E. | À³¸Ó¶}©l³zªRªvÀø(dialysis therapy) |
|
(B) | 11. |
¤@¦ì72·³¨k©Ê¦]¬°¥b¦~¨Ó¤ÏÂЦh¦¸ªc§¿¹D(UTI)·P¬V¦í°|¡A§¿²G²Óµß°ö¾i¶EÂ_¬OProteus mirabilis (>105/mL)¡A¦]¬°ªø´Á¦³¸Ñ§¿§xÃø(dysuria)»P©]§¿(nocturia)¯gª¬¡AÂå®v°µ«e¦C¸¢(prostate)IJ¶E®É¶EÂ_¦³«e¦C¸¢ªÎ¤j¥Bªí±¥·Æ¡A¦ý¬OIJ¶E®É¯f¤H¦³¯kµh¥D¶D¡C¥H¤U³B¸m¦óªÌ³Ì¤£¥¿½T?
|
A. | ¦w±ÆKUBÀˬd¬O§_¦³µ²¥Û(nephrolithiasis)©Î¨ä¥L²§±`³y¦¨¤ÏÂÐUTI |
B. | µ¹¤©bicarbonate¡AÆP¤Æ§¿²G(urine alkalization)±Æ¥X |
C. | À³¸ÓÀˬd¬O§_¦³¿}§¿¯f©ÎµÇ¥\¯à²§±` |
D. | µ¹¤©¦Ü¤Ö1-2¶g§Ü¥Í¯ÀªvÀø |
E. | ·|¶Eªc§¿¬ì |
|
(C) | 12. |
¤U¦ó¦óºØ±¡ªp·|³y¦¨§C¦å¹[¯g
1.¥NÁ©ÊÆP¤¤¬r(ÆP¦å¯g)
2.£]2-agonists
3.£\-agonists
4.¸¡Âm
5.µÇ°Ê¯ß¯U¯¶
6.µÇ¤W¸¢¥\¯à¤£¨¬
|
A. | 1,3,4 |
B. | 2,5,6 |
C. | 1,2,4,5 |
D. | 1,3,4,5 |
E. | 1,2,3,4,5 |
|
(C) | 13. |
¤@¦ì¯f¤HpH 7.26, HCO3 14 mmol/L, Na 140 mmol/L, Cl 100 mmol/L, ¤U¦Cþ¨Ç±¡ªp¸û¤£¥i¯à:
1.¨Å»Ä¤¤¬r
2.଻Ĥ¤¬r
3.µÇ°IºÜ
4.´â¤Æ»Ïµ¹¤©
5.¸¡Âm
6.µÇ¤pºÞ©Ê»Ä¤¤¬r
|
A. | 1,2 |
B. | 5,6 |
C. | 4,5,6 |
D. | 1,2,3,4 |
E. | 2,3,4,5 |
|
(D) | 14. |
³y¦¨¥NÁ©ÊÆP¤¤¬r(ÆP¦å¯g)ªº¯e¯f¡A¥i¨Ì¨ä¹ï¿é¤©§t´âÂ÷¤l·»²G§ïµ½»P§_¤À¬°´â¤ÏÀ³©Ê¤Î´â¹x§Ü©Ê¡C¤U¦C¦óºØ±¡ªp¬°´â¤ÏÀ³©Ê?
1.ìµo©Ê¥Ö½èîÇଯg
2.¨Ï¥Î«ºÒ»Ä¶u
3.¤Ú¯S¤ó¯gÔ¸s(Batter's syndrome)
4.¹Ã¦R
5.§Q§¿¾¯¨Ï¥Î
|
A. | 1,5 |
B. | 1,4,5 |
C. | 1,2,5 |
D. | 3,4,5 |
E. | 2,3,4,5 |
|
(A) | 15. |
¤U¦C¦óªÌ³Ì¤£·|³y¦¨§C¦åÁC¯g
|
A. | °Æ¥Òª¬¸¢¾÷¯à§C¤U¯g
|
B. | ºû¥Í¯ÀD¤£¨¬
|
C. | ªø´Á³¤°s
|
D. | ©I§l©ÊÆP¤¤¬r
|
E. | Fanconi's syndrome |
|
(A) | 16. |
¤@¦ì65·³¤k©ÊªA¥Î¬YÃĪ««á¥X²{¤ô¸~¤Î³J¥Õ§¿¡A¦å¤¤¥Õ³J¥Õ 2.9g/dL, µÇŦ¤Á¤ùÅã¥Üminimal change disease,¯f¤H°±¥Î¦¹ÃÄ«á³J¥Õ§¿§ïµ½¡A³Ì¥i¯àªºÃĪ«¬O
|
A. | NSAID
|
B. | Gold
|
C. | Captopril
|
D. | Allopurinol
|
E. | Amoxicillin |
|
(B) | 17. |
¤@¦ì¯f¤H¹L¥hµLµÇŦ¯f¥v¡A¤]¥¼ªA¥Î¤£©úÃĪ«¡Cªñ¤@¶g¨Óµo²{¤ô¸~¤ÎµÇ¥\¯à²§±`(creatinine 2.3mg/dL)¡A§¿²G¨I´íµo²{¬õ¦å²y¶ê¬WÅé(RBC cast)¡A¤U¦Cþ¤@¶µ¯e¯f³Ì¥i¯à:
|
A. | ½¤©ÊµÇ¯fÅÜ |
B. | §Ö³t¶i¦æ©ÊµÇµ·²yµÇª¢ |
C. | µÇ°Ê¯ß¦åºÞµw¤Æ |
D. | «æ©ÊµÇ¤pºÞÃa¦º |
E. | Åã¼v¾¯µÇ¯fÅÜ |
|
(D) | 18. |
¤@¦ì68·³¿}§¿¯f¤H¡A¨ä¦å²M¦Ù»ÄÓþ(Creatinine 3mg/dL), Âå®v³Ìªñ¥[¤F¤@¶µ°¦åÀ£ÃÄ¡A2¶g«á©â¦åcreatinine¤W¤É¦Ü6mg/dL, ¤U¦C¨º¤@ÃþÃĪ«³Ì¥i¯à³y¦¨¤Wz±¡ªp?
|
A. | £\-blockers
|
B. | £]-blockers |
C. | Calcium channel blockers |
D. | ACE inhibitors |
E. | Aldosterone antagonists |
|
(C) | 19. |
97¦~7¤ë³ø¸ü¤@¦ì¨k©ÊªA¥Î¤¤ÃÄ«á²£¥ÍµÇ°IºÜ¶·ªø´Á³zªR¡A¦¹ºØ¯f¤HªºµÇŦ¤Á¤ù¥i¨£µÇ¤pºÞ¤Î¶¡½èÅÖºû¤Æ«Ü©úÅã¦ý¸û¤Ö²ÓM®û¼í¡A¥Ø«e»{¬°¬O¨º¤@¶µª«½è¤Þµo¤Wz¯e¯f?
|
A. | ¹] |
B. | ¤ô»È(mercury) |
C. | °¨°Â¹a»Ä(aristolochic acid) |
D. | Arachidonic acid |
E. | ¤¤ÃIJK¥[¦èÃĤ§«DÃþ©T¾J®øª¢¤îµhÃÄ(NSAIDs)
|
|
(B) | 20. |
¤U¦C¦óªÌ¤£¬OµÇ©Ê°©¯fÅܪº¯fºAµo¥Í¦]¤l?
|
A. | ¬¡©Êºû¥Í¯ÀD¤£¨¬ |
B. | °ªÁâ¦å¯g
|
C. | §C¶t¦å¯g |
D. | °Æ¥Òª¬¸¢¾÷¯à¤®¶i |
E. | ¥NÁ©ʻĤ¤¬r |
|
(E) | 21. |
¤U¦C¦³Ãö³sÄò©ÊµÇŦ´À¥NÀøªk(CRRT)ªº±Ôz¦óªÌ¿ù»~:
|
A. | ¦å¦æ°Ê¤O¾ÇÅܤƸû¶¡·²©Ê¦å²G³zªR¤p |
B. | ³vº¥ÁB¥¿¯f¤H¥Í¤Æ²§±` |
C. | ¦³®Ä²¾°£¹L¦hªºÅé²G |
D. | ¦p¥ÎÀR¯ß-ÀR¯ßªvÀø¡A¦pCVVH¡A¦³®É¶·¥t¥~¥[¤@Ó¦å²GÀ°®ú±±¨î¦å¬y³t«× |
E. | Á{§É¤W°Ê¯ß-ÀR¯ßªvÀø¡A¦pCAVH¸ûCVVH±`¥Î |
|
(B) | 22. |
¥½´ÁµÇ¯f±µ¨ü¦å²G³zªR¯f¤H³zªR¨¬¶qªº³Ì§C¼Ð·Ç¬°¡G¨C¦¸³zªR¦Ü¤Ö¥i´î¤Ö¦å¤¤§¿¯À´á
|
A. | 55% |
B. | 65% |
C. | 75% |
D. | 85% |
E. | 95% |
|